MicroRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation

Biological Chemistry

Volumn 396, Issue 4, 2015, Pages 339-347

  Liu, Xiao Dong ^a   Cai, Feng ^a   Liu, Liang ^a   Zhang, Yan ^a   Yang, An Li ^a  

^a Tongji University School of Medicine   (China)

Author keywords

BMSC differentiation; miR 210; postmenopausal osteoporosis; VEGF

Indexed keywords

ALKALINE PHOSPHATASE; ESTRADIOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 210; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; TRANSCRIPTION FACTOR OSTERIX; VASCULOTROPIN; ESTROGEN; MICRORNA; MIRN210 MICRORNA, RAT; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN A;

ADIPOCYTE; ANIMAL CELL; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL STIMULATION; CELL STRUCTURE; CONTROLLED STUDY; ESTROGEN DEFICIENCY; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; OSTEOBLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; FEMALE; GENETICS; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; WISTAR RAT;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; ESTROGENS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MESENCHYMAL STROMAL CELLS; MICRORNAS; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924918590     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0268     Document Type: Article

References (50)

1. Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350-355.
2. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
3. Bonnick, S.L., Harris, S.T., Kendler, D.L., McClung, M.R., and Silverman, S.L. (2010). Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 17, 25-54; quiz 55-26.
4. Burkhardt, R., Kettner, G., Bohm, W., Schmidmeier, M., Schlag, R., Frisch, B., Mallmann, B., Eisenmenger, W., and Gilg, T. (1987). Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 8, 157-164.
5. Camps, C., Buffa, F.M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A.L., Gleadle, J.M., and Ragoussis, J. (2008). HsamiR- 210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340-1348.
6. Corina, M., Vulpoi, C., and Branisteanu, D. (2012). Relationship between bone mineral density, weight, and estrogen levels in pre and postmenopausal women. Rev. Med. Chir. Soc. Med. Nat. Iasi. 116, 946-950.
7. Crosby, M.E., Kulshreshtha, R., Ivan, M., and Glazer, P.M. (2009). MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 69, 1221-1229.
8. Ding, W.G., Wei, Z.X., and Liu, J.B. (2011). Reduced local blood supply to the tibial metaphysis is associated with ovariectomyinduced osteoporosis in mice. Connect. Tissue Res. 52, 25-29.
9. Ell, B., Mercatali, L., Ibrahim, T., Campbell, N., Schwarzenbach, H., Pantel, K., Amadori, D., and Kang, Y. (2013). Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24, 542-556.
10. Erwin, G.S., Crisostomo, P.R., Wang, Y., Wang, M., Markel, T.A., Guzman, M., Sando, L.C., Sharma, R., and Meldrum, D.R. (2009). Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. J. Surg. Res. 152, 319-324.
11. Ettinger, B., Genant, H.K., and Cann, C.E. (1985). Long-term estrogen replacement therapy prevents bone loss and fractures. Ann. Intern. Med. 102, 319-324.
12. Farh, K.K., Grimson, A., Jan, C., Lewis, B.P., Johnston, W.K., Lim, L.P., Burge, C.B., and Bartel, D.P. (2005). The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310, 1817-1821.
13. Fasanaro, P., D'Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., Capogrossi, M.C., and Martelli, F. (2008). MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem. 283, 15878-15883.
14. Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., Ivey, K.N., Bruneau, B.G., Stainier, D.Y., and Srivastava, D. (2008). miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15, 272-284.
15. Foekens, J.A., Sieuwerts, A.M., Smid, M., Look, M.P., de Weerd, V., Boersma, A.W., Klijn, J.G., Wiemer, E.A., and Martens, J.W. (2008). Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl. Acad. Sci. USA 105, 13021-13026.
16. Garnero, P. (2014). New developments in biological markers of bone metabolism in osteoporosis. Bone 66, 46-55.
17. Hamrick, M.W., Herberg, S., Arounleut, P., He, H.Z., Shiver, A., Qi, R.Q., Zhou, L., Isales, C.M., and Mi, Q.S. (2010). The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem. Biophys. Res. Commun. 400, 379-383.
18. Hu, Y.C., Cheng, H.L., Hsieh, B.S., Huang, L.W., Huang, T.C., and Chang, K.L. (2012). Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function. Bone 50, 1406-1415.
19. Huang, X., Ding, L., Bennewith, K.L., Tong, R.T., Welford, S.M., Ang, K.K., Story, M., Le, Q.T., and Giaccia, A.J. (2009). Hypoxiainducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell 35, 856-867.
20. Johnston, C.C. Jr., Hui, S.L., Witt, R.M., Appledorn, R., Baker, R.S., and Longcope, C. (1985). Early menopausal changes in bone mass and sex steroids. J. Clin. Endocrinol. Metab. 61, 905-911.
21. Kanis, J.A. (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos. Int. 4, 368-381.
22. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., and Stoffel, M. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
23. Lee, R.C., Feinbaum, R.L., Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854.
24. Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E.G., Teruya-Feldstein, J., Bell, G.W., Weinberg, R.A. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 284, 341-347.
25. Maeda, S.S., and Lazaretti-Castro, M. (2014). An overview on the treatment of postmenopausal osteoporosis. Arq. Bras. Endocrinol. Metabol. 58, 162-171.
26. Maire, G., Martin, J.W., Yoshimoto, M., Chilton-MacNeill, S., Zielenska, M., Squire, J.A. (2011). Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 204, 138-146.
27. Makins, R., and Ballinger, A. (2003). Gastrointestinal side effects of drugs. Expert Opin. Drug. Saf. 2, 421-429.
28. Manolagas, S.C. (2000). Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137.
29. Mizuno, Y., Tokuzawa, Y., Ninomiya, Y., Yagi, K., Yatsuka-Kanesaki, Y., Suda, T., Fukuda, T., Katagiri, T., Kondoh, Y., Amemiya, T., Tashiro, H., Okazaki, Y. (2009). miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett. 583, 2263-2268.
30. Nakasa, T., Ishikawa, M., Shi, M., Shibuya, H., Adachi, N., Ochi, M. (2010). Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J. Cell. Mol. Med. 14, 2495-2505.
31. Nilas, L. and Christiansen, C. (1987). Bone mass and its relationship to age and the menopause. J. Clin. Endocrinol. Metab. 65, 697-702.
32. Ohta, H., Makita, K., Suda, Y., Ikeda, T., Masuzawa, T., Nozawa, S. (1992). Influence of oophorectomy on serum levels of sex steroids and bone metabolism and assessment of bone mineral density in lumbar trabecular bone by QCT-C value. J. Bone Miner. Res. 7, 659-665.
33. Riggs, B.L., Khosla, S., Melton, L.J. (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279-302.
34. Rubin, M.R., and Bilezikian, J.P. (2003). The anabolic effects of parathyroid hormone therapy. Clin. Geriatr. Med. 19, 415-432.
35. Simon, J.A. (2012). What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 15, 3-10.
36. Street, J., Bao, M., deGuzman, L., Bunting, S., Peale, F.V. Jr., Ferrara, N., Steinmetz, H., Hoeffel, J., Cleland, J.L., Daugherty, A., et al. (2002). Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. USA 99, 9656-9661.
37. Syed, F. and Khosla, S. (2005). Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328, 688-696.
38. Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R.U., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Bader, A.G., Brown, D., et al. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18, 181-187.
39. Tazawa, H., Tsuchiya, N., Izumiya, M., and Nakagama, H. (2007). Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA 104, 15472-15477.
40. Tornero-Esteban, P., Hoyas, J.A., Villafuertes, E., Garcia-Bullon, I., Moro, E., Fernandez-Gutierrez, B., and Marco, F. (2014). Study of the role of miRNA in mesenchymal stem cells isolated from osteoarthritis patients. Rev. Esp. Cir. Ortop. Traumatol. 58, 138-143.
41. Turner, R.T., Riggs, B.L., and Spelsberg, T.C. (1994). Skeletal effects of estrogen. Endocr. Rev. 15, 275-300.
42. Tyagi, A.M., Srivastava, K., Mansoori, M.N., Trivedi, R., Chattopadhyay, N., and Singh, D. (2012). Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 7, e44552.
43. Wahid, F., Shehzad, A., Khan, T., and Kim, Y.Y. (2010) MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 1803, 1231-1243.
44. Wang, Y., Wan, C., Deng, L., Liu, X., Cao, X., Gilbert, S.R., Bouxsein, M.L., Faugere, M.C., Guldberg, R.E., Gerstenfeld, L.C., et al. (2007). The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 117, 1616-1626.
45. Wang, S., Aurora, A.B., Johnson, B.A., Qi, X., McAnally, J., Hill, J.A., Richardson, J.A., Bassel-Duby, R., and Olson, E.N. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261-271.
46. Weitzmann, M.N. and Pacifici, R. (2005). The role of T lymphocytes in bone metabolism. Immunol. Rev. 208, 154-168.
47. Wronski, T.J., Dann, L.M., Scott, K.S., and Cintron, M. (1989). Longterm effects of ovariectomy and aging on the rat skeleton. Calcif. Tissue Int. 45, 360-366.
48. Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486-491.
49. Yamasaki, K., Nakasa, T., Miyaki, S., Yamasaki, T., Yasunaga, Y., and Ochi, M. (2012). Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J. Orthop. Res. 30, 1263-1270.
50. Zhang, Z., Sun, H., Dai, H., Walsh, R.M., Imakura, M., Schelter, J., Burchard, J., Dai, X., Chang, A.N., Diaz, R.L., et al. (2009). MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8, 2756-2768.